EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin‐Mediated Amyloidosis: A Systematic Review

Zeel Vishnubhai Patel, Verkha Kumari, Paras, Bethineedi Lakshmi Deepak iD, Priyadarshi Prajjwal iD, Kolanu Nikhil Deep, Rakhi Bai, Serene Sara John iD, Omniat Amir Hussin iD

Health Science Reports · 2026-03 · 9 (3)

DOI: 10.1002/hsr2.72004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Health Science Reports, online erschienen am 04.03.2026. Verfasst von Zeel Vishnubhai Patel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Medical College Baroda Gujarat India. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hereditary transthyretin‐mediated amyloidosis (hATTR) is a disorder that affects several body systems and can result in life‐threatening conditions like cardiomyopathy and polyneuropathy. For treatment of hATTR in the new medical realm, there is a breakthrough discovery of a medicine called Eplontersen, which targets the underlying genetic mutation causing the condition. This review aims to summarize Eplontersen's mechanism of action, efficacy, safety profile, and ongoing clinical trials.

Methods

A systematic review of the literature was conducted following PRISMA guidelines. Databases searched included PubMed, Cochrane, and Science Direct using terms related to Eplontersen and hereditary amyloidosis. Studies were selected based on defined inclusion and exclusion criteria.

Results

Eplontersen was approved by the FDA after the NEURO‐TTRansform phase 3 trial showed substantial safety and efficacy. The drug demonstrated a significant reduction in serum TTR levels and improvements in neurological function and quality of life in patients with hATTR. The review also explored contraindications, dosing, safety monitoring, and patient support programs.

Conclusion

Although data gaps remain, Eplontersen represents a promising advancement in the treatment of hATTR‐induced polyneuropathy. Future research is needed on long‐term safety, early diagnosis, personalized treatments, and combination therapies. This drug emphasizes the importance of continued research for optimal patient care and outcomes.

Schlagwörter

Stichwörter der Autor:innen

antisense nucleotide analogueseplontersonhereditary amyloidosistransthyretin amyloidosisttr amyloidosis

Autor:innen und Institutionen

  • Internal Medicine Medical College Baroda Gujarat India.
  • Liaquat National Hospital and Medical College Karachi Pakistan.
  • Internal Medicine Government Medical College Patiala Punjab India.
  • Andhra Medical College Visakhapatnam Andhra Pradesh India.
  • Internal Medicine Bharati Vidyapeeth University Medical College Pune Maharashtra India.
  • Internal Medicine China Medical University Shenyang China.

ORCID-Profile: Bethineedi Lakshmi Deepak, Priyadarshi Prajjwal, Serene Sara John, Omniat Amir Hussin

Zitieren

APA

Patel, Z. V., Kumari, V., Paras, Deepak, B. L., Prajjwal, P., Deep, K. N., Bai, R., John, S. S., & Hussin, O. A. (2026). Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin‐Mediated Amyloidosis: A Systematic Review. Health Science Reports, 9(3). https://doi.org/10.1002/hsr2.72004

Vancouver

Patel ZV, Kumari V, Paras, Deepak BL, Prajjwal P, Deep KN, et al. Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin‐Mediated Amyloidosis: A Systematic Review. Health Science Reports. 2026;9(3). doi:10.1002/hsr2.72004

BibTeX
@article{Patel2026,
  author = {Patel, Zeel Vishnubhai and Kumari, Verkha and Paras and Deepak, Bethineedi Lakshmi and Prajjwal, Priyadarshi and Deep, Kolanu Nikhil and Bai, Rakhi and John, Serene Sara and Hussin, Omniat Amir},
  title = {Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin‐Mediated Amyloidosis: A Systematic Review},
  journal = {Health Science Reports},
  year = {2026},
  volume = {9},
  number = {3},
  doi = {10.1002/hsr2.72004}
}
Kostenlos starten →